The World Hypertension Market 2005-2010

Table of Contents for The World Hypertension Market 2005-2010

1. Executive Summary - Hypertension is a Dangerous Medical Condition and is a Serious Cause of Mortality Worldwide

2. Introduction to Hypertension

2.1 An Overview of Hypertension
2.2 Symptoms of Hypertension and Diagnosis of the Condition
2.3 Causes of Hypertension
2.4 Primary Hypertension
2.5 Secondary Hypertension
2.6 Pulmonary Hypertension
2.7 Epidemiology of Hypertension
2.8 Links with Other Disorders
2.9 The Treatment of Hypertension
2.9.1 Countering Hypertension Through Changes in Diet and Lifestyle - A First Line of Attack
2.9.2 Treatment Targets and the Selection of Drugs
2.9.3 Beta Blockers
2.9.4 Angiotensin Converting Enzyme (ACE) Inhibitors
2.9.5 Calcium-Channel Blockers
2.9.6 Angiotensin II Blockers
2.9.7 Alpha Blockers
2.9.8 Diuretics
2.9.9 Other Drugs
2.9.10 Treatment of Pulmonary Hypertension
2.10 The Prospects for Patients

3. The World Hypertension Market, 2004-2010

3.1 Growing Demand and Shifting Internal Dynamics in the World Antihypertensive Market, 2004-2010
3.2 Novartis to Become the Leading Company in the 2010 Hypertension Market
3.3 Angiotensin II Blockers to Continue Their Domination of the Antihypertensive Market, 2005-2010
3.4 Other Classes of Antihypertensive Drug Display High Revenues during 2004-2010
3.5 Calcium Channel Blockers - Declining Revenues due to Competition
3.6 Angiotensin Converting Enzyme (ACE) Inhibitors - Will This Class Be Superseded by the Angiotensin II Blockers?
3.7 Beta-Blockers - Carving a Secure Niche in a Highly Competitive Market
3.8 Alpha Blockers Will Maintain a Respected Position in the Hypertension Market
3.9 Increasing Potential for Blockbuster Revenues During 2004-2010
3.10 Competition in the Antihypertensive Market to Become Increasingly Intense
3.11 Monotherapy or Combination Therapy?
3.12 Diuretic Agents Retain Importance

4. The World Market for Angiotensin II Blockers, 2004-2010

4.1 Angiotensin II Blockers - Strong Growth Leads to Continuing Predominance in the Market
4.1.1 The Angiotensin II Blockers Will Benefit From More Secure Patent Protection Than The Other Classes of Antihypertensives
4.1.2 Other Advantages of Angiotensin II Blockers That Confer Important Benefits in the Market
4.2 Diovan to Take Market Leadership from Norvasc by 2010
4.2.1 Diovan Benefits from Further Clinical Studies
4.3 Cozaar/Hyzaar - High Revenues with Continued Growth
4.3.1 Further Developments for Cozaar/Hyzaar
4.4 Blopress - Another Strong Performer
4.4.1 Additional FDA Approval for Blopress
4.5 Sanofi-Aventis' Aprovel/Avapro to Maintain Steady Growth
4.5.1 Avaprovel/Avapro Benefits from Continuing Development
4.6 Bristol-Myers Squibb's Avapro/Avalide Will Also Benefit from This Growing Market
4.7 Atacand - Reversion of Licensing Rights to Original Manufacturer
4.8 Boehringer Ingelheim's Micardis Will Achieve Blockbuster Revenues By 2010
4.8.1 Micardis Shows Potential Metabolic Benefits
4.8.2 Micardis Benefits from Further Clinical Studies
4.9 Astellas Pharmaceutical's Micardis Will Achieve Very High Growth Over The Forecast Period
4.9.1 Further Clinical Studies May Confer a Market Advantage to Astellas' Micardis
4.10 Provas/Miten - Only Modest Success is Predicted for This Drug
4.11 Benicar's Revenue Growth Set to Continue Steadily
4.11.1 Further Licensing Agreements for Benicar
4.11.2 Promising Results from Further Clinical Study
4.12 The Angiotensin II Blockers: Summary and Conclusions

5. The World Market for Calcium Channel Blockers, 2004-2010

5.1 Increased Competition Will Lower Revenues
5.2 Norvasc - 2004 Market Leader Set to Lose Dominance to Leading Angiotensin II Blockers
5.2.1 Norvasc Benefits from Further Clinical Testing
5.2.2 Active Ingredient in Norvasc Combined with that of Lipitor to Form Dual Action Cardiovascular Drug
5.3 Adelat - The Second Largest Calcium Blocker, But Significantly Behind Norvasc
5.4 Plendil - Declining Revenues Predicted
5.5 Coniel Will Sustain Revenues
5.6 Herbesser Faces Slight Decline in Revenues
5.6.1 The Outcome of Further Clinical Studies on Herbesser
5.7 Lercanidipine - Optimism Due to Further Launches and Product Development
5.7.1 Lercandipine to Be Released in More Countries
5.7.2 Lercandipine Receives Continuing Product Development
5.8 Perpidine/Perpidine LA - Revenue Decline Predicted
5.9 Calslot Will Show Moderate Revenue Growth
5.10 Lower Revenue Calcium Blockers: Nivadil, Verelan PM and Cardizem LA
5.10.1 Cardizem LA Is Undergoing Further Development
5.11 The Calcium Blockers: Summary and Conclusions

6. The World Market for Angiotensin Converting Enzyme (ACE) Inhibitors, 2004-2010

6.1 How Well Will The ACE Inhibitors Resist Competition From The Angiotensin II Blockers?
6.1.1 ACE Inhibitors Will Retain Prominence in The Market
6.2 Delix/Tritace Will Lose Predominance In This Class
6.2.1 Licensing Agreements for International Distribution
6.2.2 Further Clinical Studies and Life Cycle Management to Confer Benefits to Delix/Tritace
6.3 Lotrel Will Become The ACE Inhibitor With The Highest Revenues
6.4 Vasotec/Vaseretic - This Older Drug Will Face Decline
6.4.1 Additional Clinical Studies and Product Development to Benefit Vasotec
6.5 Accupril/Accuretic - Revenues Set To Fall
6.5.1 Accupril/Accuretic Faces Patent Challenges
6.6 Zestril - Expiry of Patent Leads to Continuing Decline
6.7 Monopril Faces a Steep Decline In Revenue
6.8 Tanatril Is Likely to Struggle to Maintain Revenues
6.9 ACE Inhibitors With Lower Revenues: Acecol and Longes
6.10 The ACE inhibitors: Summary and Conclusions

7. The World Market for Beta-Blockers, 2004-2010

7.1 Beta Blockers Will Retain Their Niche in a Highly Competitive Market
7.1.1 Uses and Limitations of Beta Blockers That Affect Their Position In The Market
7.2 Toprol-XL/Seloken Will Become the Second Most Important Beta Blocker
7.2.1 Toprol-XL Faces Patent Challenges
7.3 Coreg Is Set to Lead the Beta Blocker Class
7.3.1 Coreg May Benefit From Further Clinical Studies
7.4 Maintate Faces Declining Revenues
7.5 The Beta Blockers: Summary and Conclusions

8. The World Market for Alpha Blockers, 2004-2010

8.1 Alpha blockers Will Defend Their Position in the Hypertension Market
8.1.1 Alpha Blockers Are Also Used to Treat BPH
8.1.2 Limitations On The Use of Alpha Blockers Influence Their Performance in The Market
8.2 Cardura Will Dominate the Alpha Blocker Class
8.3 Catapresan Will Be Second Largest Drug In Its Class
8.4 Ebrantil Will Have Lowest Market Share in Class
8.5 The Alpha Blockers: Summary and Conclusions

9. An Analysis of Factors That Influence the Hypertension Market

9.1 SWOT Analysis of the Hypertension Market
9.2 An Expanding Patient Population Constitutes the Principal Driver in the Hypertension Market
9.3 The Hypertension Market Has Opportunities for Continuing Growth
9.4 Changes in Blood Pressure Treatment Guidelines - Can Both Patients and Drug Companies Benefit?
9.5 Advances in Technology Are Likely to Bring Benefits to the Market
9.6 The Principal Restraints in the Hypertension Market
9.7 To What Extent is the Hypertension Market Threatened by Generic Substitutes?
9.8 What Unmet Market Needs Exist in the Hypertension Market? - Experts Provide Their Views
9.8.1 Resistant Hypertension Constitutes a Major Limitation of Present Treatments
9.8.2 Important Patient Sub-Populations: Potential For Companies To Increase Market Leverage Through Product Differentiation
9.9 Comparative Studies - A Two Edged Sword

10. A Geographical Breakdown of the World Hypertension Market

10.1 The US Will Lead a High Revenue Global Market in 2010
10.2 The Prevalence of Hypertension Worldwide - Many Hypertensive People Currently Untreated or Under-treated
10.3 Conclusions: There is An Urgent Requirement To Expand the Treatment of Hypertension on a Global Scale

11. Pipeline Drugs for Hypertension

11.1 Agents in Phase II of Clinical Development
11.1.1 Darusentan From Myogen
11.1.2 MC-4232 From Medicure
11.1.3 MC-1 From Medicure
11.1.4 MC-4262 From Medicure
11.1.5 Ventavis From CoTherix For More Specialised Indication
11.2 Agents in Phase III of Clinical Development
11.2.1 Aliskiren (SPP100) From Novartis
11.2.2 Ambrisentan From Myogen
11.2.3 Thelin From Encysive
11.2.4 PW2101 From Penwest
11.2.5 (S)-amlodipine From Sepracor
11.3 Recently Approved Agents for Treating Hypertension
11.3.1 Revatio From Pfizer
11.3.2 Nebivolol From Mylan
11.3.3 Ventavis From CoTherix
11.3.4 Ventavis Monopril-HCT From Ranbaxy
11.3.5 Hydrochlorothiazide From Ivax
11.3.6 Other Recently Approved Agents for Hypertension
11.4 An Overall Assessment of Pipeline Developments for the Hypertension Market

12. Conclusions: Hypertension Constitutes a Large Drugs Market With Scope For Expansion Worldwide

12.1 Hypertension is a Serious, Growing Problem Worldwide
12.2 Hypertension Constitutes a High Revenue Market with Continuing Growth Potential
12.3 Hypertension Drugs will Achieve High Revenues in all the Major Geographical Markets from 2005-2010
12.4 The Pipeline for Hypertension Drugs is Strong
12.5 Continuing Public and Private Sector Investment is Required

TABLES

Table 2.1, Categories for Blood Pressure Levels in Adults
Table 2.2, Leading Beta-Blockers to Treat Hypertension, 2004
Table 2.3, Leading ACE Inhibitors to Treat Hypertension
Table 2.4, Leading Calcium Channel Blockers to Treat Hypertension
Table 2.5, Leading Angiotensin II Blockers to Treat Hypertension
Table 2.6, Leading Alpha Blockers to Treat Hypertension, 2004
Table 3.1, Blockbuster Drugs in the World Hypertension Market, 2004
Table 3.2, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2004-2010
Table 3.3, World Market Revenue ($m) and Market Share (%) for Leading Hypertension Drugs by Class, 2010
Table 3.4, Blockbuster Drugs in the World Hypertension Market, 2010
Table 4.1, World Revenues ($m) for Angiotensin II Blockers, 2004-2010
Table 4.2, Patent Expiry for Angiotensin II Blockers, 2005
Table 4.3, World Market Shares (%) for Angiotensin II Blockers, 2004 and 2010
Table 5.1, World Revenues ($m) for Calcium Channel Blockers, 2004-2010
Table 5.2, Patent Expiry for Calcium Channel Blockers to Treat Hypertension
Table 5.3, World Market Shares (%) for Calcium Blockers, 2004 and 2010
Table 6.1, World Revenues ($m) for ACE Inhibitors, 2004-2010
Table 6.2, Patent Expiry for ACE Inhibitors to Treat Hypertension
Table 6.3, World Market Shares (%) for ACE Inhibitors, 2004 and 2010
Table 7.1, World Revenues ($m) for Beta-Blockers, 2004-2010
Table 7.2, Patent Expiry for Beta-Blockers to Treat Hypertension
Table 7.3, World Market Shares (%) for Beta Blockers, 2004 and 2010
Table 8.1, World Revenues ($m) for Alpha Blockers, 2004-2010
Table 8.2, Patent Expiry for Alpha Blockers to Treat Hypertension
Table 8.3, World Market Shares (%) for Alpha Blockers, 2004 and 2010
Table 9.1, Leading Antihypertensive Drugs That Face The Greatest Threat From Generic Competition, 2005
Table 10.1, Estimated Hypertensive Patient Populations by Country, 2004
Table 10.2, Estimated Revenues ($m) For Hypertension Drugs by Country and (%) World Market Shares, 2004 and 2010
Table 12.1, World Market Revenue ($m) and Market Share (%) for Leading Hypertension Drugs by Class, 2010
Table 12.2, Revenues ($m) For Hypertension Drugs by Country, 2010

FIGURES

Figure 3.1, World Revenues ($m) for the Classes of Leading Drugs to Treat Hypertension, 2004-2010
Figure 3.2, World Market Share (%) for Hypertension by Class, 2004
Figure 3.3, World Market Share (%) for Hypertension by Class, 2010
Figure 3.4, Market Share (%) for Leading Hypertension Drugs by Company, 2004
Figure 3.5, Market Share (%) for Leading Hypertension Drugs by Company, 2010
Figure 3.6, Changes ($m) in World Revenues for the Classes of Hypertension Drugs, 2004-2010
Figure 3.7, Changes (%) in World Revenues for the Classes of Hypertension Drugs, 2004-2010
Figure 4.1, World Revenues ($m) for All Angiotensin II Blockers, 2004-2010
Figure 4.10, World Micardis (Boehringer Ingelheim) Revenues ($m), 2004-2010
Figure 4.11, World Micardis (Astellas Pharma) Revenues ($m), 2004-2010
Figure 4.12, World Provas/Miten Revenues ($m), 2004-2010
Figure 4.13, World Benicar Revenues ($m), 2004-2010
Figure 4.2, World Revenues ($m) for the Angiotensin II Blockers by drug, 2004-2010
Figure 4.3, World Market Share (%) for Angiotensin II Blockers, 2004
Figure 4.4, World Market Share (%) for the Angiotensin II Blockers, 2010
Figure 4.5, World Diovan/Co-Diovan Revenues ($m), 2004-2010
Figure 4.6, World Cozaar/Hyzaar Revenues ($m), 2004-2010
Figure 4.7, World Blopress Revenues ($m), 2004-2010
Figure 4.8, World Aprovel/Avapro Revenues ($m), 2004-2010
Figure 4.9, World Avapro/Avalide Revenues ($m), 2004-2010
Figure 5.1, World Revenue ($m) for Calcium Channel Blockers, 2004-2010
Figure 5.10, World Lercandidipine Revenues ($m), 2004-2010
Figure 5.11, World Perpidine/Perpidine LA Revenues ($m), 2004-2010
Figure 5.12, World Calslot Revenues ($m), 2004-2010
Figure 5.13, World Nivadil Revenues ($m), 2004-2010
Figure 5.14, World Verelan PM Revenues ($m), 2004-2010
Figure 5.15, Cardizem LA Revenues ($m), 2004-2010
Figure 5.2, World Revenues ($m) for Calcium Channel Blockers, 2010
Figure 5.3, World Market Share (%) for Calcium Channel Blockers, 2004
Figure 5.4, World Market Share (%) for Calcium Channel Blockers, 2010
Figure 5.5, World Norvasc Revenues ($m), 2004-2010
Figure 5.6, World Adalat Revenues ($m), 2004-2010
Figure 5.7, World Plendil Revenues ($m), 2004-2010
Figure 5.8, World Coniel Revenues ($m), 2004-2010
Figure 5.9, World Herbesser Revenues ($m), 2004-2010
Figure 6.1, World Revenue ($m) for All ACE Inhibitors, 2004-2010
Figure 6.10, World Monopril Revenues ($m), 2004-2010
Figure 6.11, World Tanatril Revenues ($m), 2004-2010
Figure 6.12, World Acecol Revenues ($m), 2004-2010
Figure 6.13, World Longes Revenues ($m), 2004-2010
Figure 6.2a, World Revenues ($m) for the ACE Inhibitors, 2004-2010
Figure 6.2b, World Revenues ($m) for Monopril, Tanatril, Acecol & Longes, 2004-2010
Figure 6.3, World Market Share (%) for ACE Inhibitors, 2004
Figure 6.4, World Market Share (%) for ACE Inhibitors, 2010
Figure 6.5, World Delix/Tritace Revenues ($m), 2004-2010
Figure 6.6, World Lotrel Revenues ($m), 2004-2010
Figure 6.7, World Vasotec/Vaseretic Revenues ($m), 2004-2010
Figure 6.8, World Accupril/Accuretic Revenues ($m), 2004-2010
Figure 6.9, World Zestril Revenues ($m), 2004-2010
Figure 7.1, World Revenues ($m) for the Beta Blockers: Total for Class, 2004-2010
Figure 7.2, World Revenues ($m) for the Beta Blockers, 2004-2010
Figure 7.3, World Market Share (%) for Beta-Blockers, 2004
Figure 7.4, World Market Share (%) for Beta-Blockers, 2010
Figure 7.5, World Toprol-XL/Seloken Revenues ($m), 2004-2010
Figure 7.6, World Coreg Revenues ($m), 2004-2010
Figure 7.7, World Maintate Revenues ($m), 2004-2010
Figure 8.1, World Revenues ($m) for the Alpha Blockers: Total for Market, 2004-2010
Figure 8.2, World Revenues ($m) for the Alpha Blockers, 2004-2010
Figure 8.3, World Market Share (%) for Alpha Blockers, 2004
Figure 8.4, World Market Share (%) for Alpha Blockers, 2010
Figure 8.5, World Cardura Revenues ($m), 2004-2010
Figure 8.6, Catapresan Revenues ($m), 2004-2010
Figure 8.7, Ebrantil Revenues ($m), 2004-2010
Figure 9.1, A SWOT Chart for the Hypertension Market, 2005-2010
Figure 10.1, Estimated Hypertensive Populations by Country
Figure 10.2, Revenues ($m) for Hypertension Drugs by Country, 2010

CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: jenniferc@cmsinfo.com

For more information about us, visit CMSinfo.